New Possibilities for Evaluating Markers of Alzheimer's Disease in Blood Serum

New Possibilities for Evaluating Markers of Alzheimer's Disease in Blood Serum

Given the steady increase in the number of cases of Alzheimer's disease, the issue of improving the level of its diagnosis is becoming more urgent. The aim of the study was to develop a new method for verifying markers of Alzheimer's disease in blood serum based on graphene sensors. Ma...

Full description

Saved in:

Bibliographic Details
Main Authors:	S. V. Vorobev, A. Yu. Plekhanov, I. K. Ternovykh, A. S. Usikov, A. А. Lebedev, A. N. Smirnov, N. M. Shmidt, M. S. Dunaevskiy, S. P. Lebedev
Format:	Article
Language:	Russian
Published:	LLC "Publishing House OKI" 2025-06-01
Series:	Антибиотики и Химиотерапия
Subjects:	graphene biosensor alzheimer's disease beta-amyloid tau protein neurodegeneration biomarkers
Online Access:	https://www.antibiotics-chemotherapy.ru/jour/article/view/1220
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Autophagy and Alzheimer’s Disease: Mechanisms and Impact Beyond the Brain
by: Zaw Myo Hein, et al.
Published: (2025-06-01)

Blood essential trace elements and Alzheimer’s disease biomarkers in midlife
by: Xin Wang, et al.
Published: (2025-05-01)

The origin of Alzheimer’s disease: Prions?
by: Dongchuan Yang, et al.
Published: (2025-05-01)

APOE GENE POLYMORPHISM: THE IMPACT OF APOE4 ALLELE ON SYSTEMIC INFLAMMATION AND ITS ROLE IN THE PATHOGENESIS OF ALZHEIMER’S DISEASE
by: I. K. Malashenkova, et al.
Published: (2018-06-01)

Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort
by: Menayit Tamrat Dresse, et al.
Published: (2025-07-01)

Associations of Plasma and CSF Osteocalcin Levels With CSF ATN Biomarkers and Cognitive Functions in Alzheimer's Disease
by: Xian‐Le Bu, et al.
Published: (2025-07-01)

Novel targets for the treatment and prevention of Alzheimer's disease in the European population, inspiration from amyloid beta and tau protein
by: Xifeng Wang, et al.
Published: (2024-10-01)

Analysis of cognitive status of Alzheimer’s disease’s subjects and its association with biomarkers (amyloid beta and tau proteins) using NACC data
by: Vaghawan Prasad Ojha, et al.
Published: (2025-04-01)

The intersection between circulatory microRNAs and biomarkers of neurodegeneration
by: Amber Yaqub, et al.
Published: (2025-07-01)

Rest‐activity rhythm characteristics associated with lower cognitive performance and Alzheimer's disease biomarkers in midlife women
by: Alexandra Paget‐Blanc, et al.
Published: (2025-04-01)

The Potential Mechanism and the Role of Antioxidants in Mitigating Oxidative Stress in Alzheimer’s Disease
by: Rayees Ahmad Naik, et al.
Published: (2025-02-01)

Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A<sup>+</sup>T<sup>+</sup> (A<sup>+</sup>T<sub>1</sub><sup>+</sup>) Alzheimer’s Disease
by: Ioanna Tsantzali, et al.
Published: (2024-12-01)

Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
by: Mandić Gorana, et al.
Published: (2008-01-01)

Chronic administration of prebiotics and probiotics prevent pathophysiological hallmarks of Alzheimer’s disease in the cortex of APP/PS1 mice
by: Giorgia Sarti, et al.
Published: (2025-05-01)

Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species
by: Cynthia J. Siebrand, et al.
Published: (2025-05-01)

Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies
by: Yunkwon Nam, et al.
Published: (2025-03-01)

Stamp-Imprinted Polymer EIS Biosensor for Amyloid-Beta Detection: A Novel Approach Towards Alzheimer’s Screening
by: Chloé E. D. Davidson, et al.
Published: (2025-04-01)

A systematic review of Alzheimer's disease: exploring genetic and environmental risk factors, biomarkers, and future pharmacotherapy for cognitive decline and neurodegeneration
by: Debraj Dey, et al.
Published: (2025-06-01)

Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer’s Disease Therapeutics
by: Daniela Dias, et al.
Published: (2025-01-01)

Molecular Mechanisms of Alzheimer’s Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy
by: Eun Hee Ahn, et al.
Published: (2025-01-01)

sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease
by: Davina Biel, et al.
Published: (2023-01-01)

Non-mutated human tau stimulates Alzheimer’s disease-relevant neurodegeneration in a microglia-dependent manner
by: Ethan R. Roy, et al.
Published: (2025-07-01)

Dietary Strategies to Mitigate Alzheimer’s Disease: Insights into Antioxidant Vitamin Intake and Supplementation with Microbiota–Gut–Brain Axis Cross-Talk
by: Wan Zurinah Wan Ngah, et al.
Published: (2024-12-01)

Inflammasome-Mediated Neuroinflammation: A Key Driver in Alzheimer’s Disease Pathogenesis
by: Julie McGroarty, et al.
Published: (2025-05-01)

Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients
by: Hyuk Sung Kwon, et al.
Published: (2025-03-01)

The mechanism underlying streptozotocin injection for the development of a nontransgenic Alzheimer's disease animal model
by: Nurina Titisari, et al.
Published: (2025-02-01)

Sensitivity analysis of a mathematical model of Alzheimer's disease progression unveils important causal pathways
by: Seyedadel Moravveji, et al.
Published: (2025-07-01)

Sleep reduces CSF concentrations of beta-amyloid and tau: a randomized crossover study in healthy adults
by: Tim Lyckenvik, et al.
Published: (2025-08-01)

Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
by: Sha Sha, et al.
Published: (2026-02-01)

Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease
by: Tapas K. Sur, et al.
Published: (2025-06-01)

Strategies for Treating Alzheimer’s: Current Approaches and Future Perspectives
by: Adriana Skuba, et al.
Published: (2025-05-01)

Advanced Biosensing Technologies: Leading Innovations in Alzheimer’s Disease Diagnosis
by: Stephen Rathinaraj Benjamin, et al.
Published: (2025-06-01)

Comparisons of efficacy and safety of immunotherapies for Alzheimer’s disease treatment: A network meta-analysis of randomised controlled trials
by: Ching-Hui Su, et al.
Published: (2025-07-01)

Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives
by: Mohammed Alrouji, et al.
Published: (2025-06-01)

The effects of a bioavailable curcumin formulation on Alzheimer's disease pathologies: A potential risk for neuroinflammation
by: Shaun Cade, et al.
Published: (2024-12-01)

Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
by: Eliasz Engelhardt, et al.
Published: (2024-12-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
by: Alexandra Wicker, et al.
Published: (2024-10-01)

Impact of hyaluronic acid-modified hafnium metalorganic frameworks containing rhynchophylline on Alzheimer’s disease
by: Lin Shiguo, et al.
Published: (2025-03-01)

Cell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
by: Michael Okafor, et al.
Published: (2025-08-01)